BioAdaptives

BioAdaptives OCF Margin

The Operating Cash Flow Margin of BioAdaptives (BDPT) as of Oct 26, 2026 is -2,823.20 %. In the previous year, Operating Cash Flow Margin was -1,969.51 % — a change of 43.35% (lower).

OCF Margin

-2,823.20 %

YoY

43.35%

Last updated:

Operating Cash Flow Margin of BioAdaptives is 2025 -2,823.20 % . Operating Cash Flow Margin of BioAdaptives was 2024 -1,969.51 % . It decreases by 43.35% lower compared to the previous year.

The BioAdaptives OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2016
29.26 USD
Jan 1, 2019
-1,692.37 USD
Jan 1, 2020
-654.68 USD
Jan 1, 2021
-802.24 USD
Jan 1, 2022
-1,323.12 USD
Jan 1, 2023
-783.38 USD
Jan 1, 2024
-1,969.51 USD
Jan 1, 2025
-2,823.20 USD
The BioAdaptives OCF Margin history
YEAROCF MarginYoY
-2,823.20 %+43.35%
-1,969.51 %+151.41%
-783.38 %-40.79%
-1,323.12 %+64.93%
-802.24 %+22.54%
-654.68 %-61.32%
-1,692.37 %-5,883.15%
29.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioAdaptives stock

Operating Cash Flow Margin of BioAdaptives is -2,823.20 % in 2025.

Operating Cash Flow Margin of BioAdaptives changed from -1,969.51 % to -2,823.20 %, representing a 43.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's BioAdaptives with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — BioAdaptives

All Key Metrics — BioAdaptives